Table 3.
Identified drivers and enablers in the Swedish healthcare system to leverage competition from biosimilars
| Drivers | Enablers | |
|---|---|---|
| Quantitative study | Qualitative study | |
| The difference in discounted price per DDD between the biosimilar and the originator product (potential savings) |
The difference in discounted price per DDD Key opinion leaders Local guidelines Gainsharing |
A multi-stakeholder approach An altruistic attitude Good communication with colleagues |
DDD defined daily dose